| Literature DB >> 32276433 |
Anna Adamiok-Ostrowska1, Agnieszka Piekiełko-Witkowska1.
Abstract
Cilia are microtubule-based organelles, protruding from the apical cell surface and anchoring to the cytoskeleton. Primary (nonmotile) cilia of the kidney act as mechanosensors of nephron cells, responding to fluid movements by triggering signal transduction. The impaired functioning of primary cilia leads to formation of cysts which in turn contribute to development of diverse renal diseases, including kidney ciliopathies and renal cancer. Here, we review current knowledge on the role of ciliary genes in kidney ciliopathies and renal cell carcinoma (RCC). Special focus is given on the impact of mutations and altered expression of ciliary genes (e.g., encoding polycystins, nephrocystins, Bardet-Biedl syndrome (BBS) proteins, ALS1, Oral-facial-digital syndrome 1 (OFD1) and others) in polycystic kidney disease and nephronophthisis, as well as rare genetic disorders, including syndromes of Joubert, Meckel-Gruber, Bardet-Biedl, Senior-Loken, Alström, Orofaciodigital syndrome type I and cranioectodermal dysplasia. We also show that RCC and classic kidney ciliopathies share commonly disturbed genes affecting cilia function, including VHL (von Hippel-Lindau tumor suppressor), PKD1 (polycystin 1, transient receptor potential channel interacting) and PKD2 (polycystin 2, transient receptor potential cation channel). Finally, we discuss the significance of ciliary genes as diagnostic and prognostic markers, as well as therapeutic targets in ciliopathies and cancer.Entities:
Keywords: OFD1; PKD1; PKD2; RCC; VHL; ciliopathies; nephronophthisis; polycystic kidney disease; primary cilia; renal cell cancer
Mesh:
Substances:
Year: 2020 PMID: 32276433 PMCID: PMC7226761 DOI: 10.3390/cells9040907
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1The structure of primary cilium. The axoneme is composed of nine pairs of microtubules, anchored in the cell by the basal body. The latter is a modified centriole, consisting of nine triplets of microtubules. The mother centriole plays a key role in ciliogenesis, recruiting the molecules required for axoneme elongation. The daughter centriole results from duplication of mother centriole during S phase [4]). The arrows indicate the key structural cilium elements (the axoneme, transition zone and basal body) as well as proteins involved in kidney ciliopathies and renal cell carcinoma (RCC) [4,5,17,18].
Figure 2The structure of polycystins. LRR: leucine-rich repeats; WSC: cell wall integrity and stress response component domain; Lectin C: lectin C type-3 domain; LDL-A: low-density lipoprotein-A domain, PKD: polycystic kidney disease repeats; GAIN: G-protein-coupled receptor (GPCR) autoproteolysis-inducing domain, PLAT: Polycystin-1, Lipoxygenase, Alpha-Toxin domain. The Figure reprinted and modified with permission from [45] under Creative Commons Attribution 4.0 International (CC BY 4.0).
Cilia and renal cysts-associated diseases.
| Diseases | Mutated Genes | Features |
|---|---|---|
| PKD | Renal cyst formation | |
| Meckel-Gruber syndrome | Renal cyst formation | |
| Nephronophthisis | Renal fibrosis and cyst formation | |
| Joubert syndrome | Renal cyst formation | |
| Oral-facial-digital syndrome type I |
| Cystic kidney disease |
| Cranioectodermal dysplasia | Renal failure | |
| Bardet-Biedl | Chronic renal failure in children | |
| Senior-Loken syndrome | Juvenile nephronophthisis, renal cyst | |
| Alström syndrome |
| Renal failure |
| RCC | Cyst and cancer | |
| Von Hippel-Lindau |
| Cyst and cancer |
Examples of ciliary genes use in cancer clinical trials (from TTD—Therapeutic Target Database http://db.idrblab.net/ttd/ (accessed on 6 November 2019) [178].
| Ciliary Genes | Type of Cancer | Name of Drug | Clinical Trial | References |
|---|---|---|---|---|
|
| Solid cancer | Recombinant human endostatin | approved | [ |
|
| Solid cancer | DS-8273 | Phase1 |
|
|
| Acute myeloid leukemia, osteosarcoma | LY2090314, | Phase2 | |
|
| Solid cancer, Acute myeloid leukemia | Rigosertib, | Phase3, | [ |
|
| Solid cancer, skin cancer | LDE225 | Approved (basal cell carcinoma) | [ |
|
| Solid cancer | BAY1161909, | Phase1 | [ |
|
| Solid cancer | PRLX93936 | Phase1/2 |
|
|
| Renal cell cancer | Pyrrolidine carboxamide derivative 1 | Patented-recorded Target | [ |
List of ciliary genes as diagnostic, prognostic, theragnostic or associative biomarkers (from TTD—Therapeutic Target Database http://db.idrblab.net/ttd/ (accessed on 6 November 2019) [178].
| Ciliary Genes | Biomarker Gene Location | Disease | Biomarker Type | Molecular Type | Biomarker Measure | Interactors | Reference |
|---|---|---|---|---|---|---|---|
|
| 16p13.3 | Polycystic kidney disease | Prognostic | Gene | Mutation | - | [ |
|
| 16p13.3 | Acute kidney injury, | Diagnostic, | Protein | Elevated level | - | [ |
|
| 5q35.1 | Hypertension | Associative | Gene | SNP | - | [ |
|
| 11q23.2 | Hypertension, schizophrenia | Associative, Theragnostic | Gene | SNP | - | [ |
|
| 19q13.33 | Psoriatic arthitis | Diagnostic | Gene | Expression | - | [ |
|
| 9q22.32- | Medulloblastoma | Theragnostic | Gene | Mutation | - | [ |
|
| 7q32.1- | Medulloblastoma | Theragnostic | Gene | Mutation | - | [ |
|
| 16q24.3 | Non-small cell lung cancer | Prognostic | Protein | Absence | ERCC1 | [ |
-: unknown.